Suggested Remit: To appraise the clinical and cost effectiveness of IMCgp100 within its marketing authorisation for treating uveal melanoma.
Status In progress
Process STA 2018
ID number 1441

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
03 April 2019 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
27 November 2018 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of IMCgp100 for treating metastatic uveal melanoma. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that is developing IMCgp100, NICE has agreed that a scoping exercise at this time would not be appropriate. Consequently the consultation on the draft scope will be closed and scoping workshop arranged for the 21 January 2019 will be cancelled. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at
31 July 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance